Understanding the Tuberculosis Disease Progression and Future Directions of Research in Tuberculosis: A Mini Review
-
Vol. 13 No. 1 : 2018 (20-28)
Abstract
Eradication of tuberculosis seems to be a long way off especially with the growing of drug resistance tuberculosis and HIV co-infection tuberculosis. The gaps in our knowledge and the limited sensitive and specific biomarkers especially for latent tuberculosis infection make it defensive. The fate of tuberculosis treatment ranged from cured to failure and there are many risk factors involved apart from the immune state and age. Therefore, this review focuses on the understanding of tuberculosis disease progression and the associated risk factors of the events in the disease progression. This article also highlights the diagnostic and predictive marker that may predict the disease progression. In addition, this review highlights the potential use of rifabutin in tuberculosis treatment regimen. It is hoped that this review could give an overview on future directions of research in tuberculosis.
Keywords :
Biomarkers,
disease progression,
rifabutin,
risk factors,
tuberculosis,
Correspondance Address
Address for correspondence and reprint requests: Hawa Nordin Siti. Department of Basic Medical
Sciences, Faculty of Medicine, Universiti Sultan Zainal Abidin, Jalan Sultan Mahmud, 20400 Kuala
Terengganu, Terengganu, Malaysia. Tel: +609 6688515 E-mail: hawanordin@gmail.com
References
Chien, J.Y., Chien, S.T., Huang, S.Y., Yu, C.J. 2013.
Safety of rifabutin replacing rifampicin in
the treatment of tuberculosis: a single-centre
retrospective cohort study. J Antimicrob
Chemother 69(3): 790-6.
Crook, A.M., Turkova, A., Musiime, V., Bwakura-
Dangarembizi, M., Bakeera-Kitaka, S., Nahirya-
Ntege, P., Thomason, M., Mugyenyi, P.,
Musoke, P., Kekitiinwa, A., Munderi, P., Nathoo,
K., Prendergast, A.J., Walker, A.S., Gibb, D.M.
2016. Tuberculosis incidence is high in HIVinfected
African children but is reduced by
co-trimoxazole and time on antiretroviral
therapy. BMC Med 14: 50.
Evangelopoulos, D., Whittaker, E., Honeyborne,
I., McHugh, T.D., Klein, N., Shingadia,
D. 2017. Pediatric tuberculosis-human
immunodeficiency virus co-infection in the
United Kingdom highlights the need for better
therapy monitoring tools: a case report. J Med
Case Rep 11(1): 52.
Jo, K.W., Ji, W., Hong, Y., Lee, S.D., Kim, W.S., Kim,
D.S., Shim, T.S. 2013. The efficacy of rifabutin
for rifabutin-susceptible, multidrug-resistant
tuberculosis. Respir Med 107(2): 292-7.
Kiran, D., Podell, B.K., Chambers, M., Basaraba,
R.J. 2016. Host-directed therapy targeting
the Mycobacterium tuberculosis granuloma: a
review. Semin Immunopathol 38(2): 167–83.
Kizza, F.N., List, J., Nkwata, A.K., Okwera, A.,
Ezeamama, A.E., Whalen, C.C., Sekandi, J.N.
2015. Prevalence of latent tuberculosis infection
and associated risk factors in an urban African
setting. BMC Infect Dis 15:165.
Kok, H.S., Tara, M.G., Mae-Lynn, C.B., Muhaya,
H.M. 2006. Two cases of retinal vasculitis in
ocular tuberculosis involving different parts of
the vascular system. Med & Health 1(1): 91-3.
Lai, R.P., Meintjes, G., Wilkinson, R.J. 2016. HIV-1
tuberculosis-associated immune reconstitution
inflammatory syndrome. Semin Immunopathol
38(2): 185–98.
Lan, N.T., Thu, N.T., Barrail-Tran, A., Duc, N.H.,
Lan, N.N., Laureillard, D., Lien, T.T., Borand,
L., Quillet, C., Connolly, C., Lagarde, D.,
Pym, A., Lienhardt, C., Dung, N.H., Taburet,
A.M., Harries, A.D. 2014. Randomised
pharmacokinetic trial of rifabutin with lopinavir/
ritonavir-antiretroviral therapy in patients with
HIV-associated tuberculosis in Vietnam. PLoS
One 9(1): e84866.
Lawn, S.D., Meintjes, G., McIlleron, H., Harries, A.D.,
Wood, R. 2013. Management of HIV-associated
tuberculosis in resource-limited settings: a stateof-
the-art review. BMC Med 11: 253.
Ma, N., Zalwango, S., Malone, L.L., Nsereko, M.,
Wampande, E.M., Thiel, B.A., Okware, B.,
Igo, R.P., Joloba, M.L., Mupere, E., Mayanja-
Kizza, H., Boom, W.H., Stein, C.M. 2014.
Clinical and epidemiological characteristics of
individuals resistant to M. tuberculosis infection
in a longitudinal TB household contact study in
Kampala, Uganda. BMC Infect Dis 14: 352.
Mancini, P., Pasqua, F., Mazzei, L., Olliaro, P. 1992.
Rifabutin treatment for tuberculosis patients
with liver function abnormalities. J Antimicrob
Chemother 30(2): 242.
Martínez, E., Collazos, J., Mayo, J. 1999.
Hypersensitivity reactions to rifampin:
pathogenetic mechanisms, clinical
manifestations, management strategies,
and review of the anaphylactic-like
reactions. Medicine (Baltimore) 78(6): 361-9.
Moreno, V., Espinoza, B., Barley, K., Paredes, M.,
Bichara, D., Mubayi, A., Castillo-Chavez,
C. 2017. The role of mobility and health
disparities on the transmission dynamics of
Tuberculosis. Theor Biol Med Model 14(1): 3.
Moultrie, H., McIlleron, H., Sawry, S., Kellermann,
T., Wiesner, L., Kindra, G., Van Rie, A. 2014.
Pharmacokinetics and safety of rifabutin
in young HIV-infected children receiving
rifabutin and lopinavir/ritonavir. J Antimicrob
Chemother 70(2): 543-9.
Mpagama, S.G., Houpt, E.R., Stroup, S., Kumburu,
H., Gratz, J., Kibiki, G.S., Heysell, S.K. 2013.
Application of quantitative second-line drug
susceptibility testing at a multidrug-resistant
tuberculosis hospital in Tanzania. BMC Infect
Dis 13(1): 432.
Naiker, S., Connolly, C., Wiesner, L., Kellerman, T.,
Reddy, T., Harries, A., McIlleron, H., Lienhardt,
C. Pym, A. 2014. Randomized pharmacokinetic
evaluation of different rifabutin doses in African
HIV- infected tuberculosis patients on lopinavir/
ritonavir-based antiretroviral therapy. BMC
Pharmacol Toxicol 15: 61.
Oberhelman, R.A., Soto-Castellares, G., Gilman,
R.H., Castillo, M.E., Kolevic, L., Delpino,
T., Saito, M., Salazar-Lindo, E., Negron, E.,
Montenegro, S., Laguna-Torres, V.A., Maurtua-
Neumann, P., Datta, S., Evans, C.A. 2015.
A controlled study of tuberculosis diagnosis
in HIV-infected and uninfected children in
Peru. PLoS One 10(4): e0120915.
Phillips, P.P., Mendel, C.M., Burger, D.A., Crook,
A.M., Nunn, A.J., Dawson, R., Diacon, A.H.,
Gillespie, S.H. 2016. Erratum to: Limited role
of culture conversion for decision-making in
individual patient care and for advancing novel
regimens to confirmatory clinical trials. BMC
Med 14: 36.
Pullar, N.D., Steinum, H., Bruun, J.N., Dyrhol-Riise,
A.M. 2014. HIV patients with latent tuberculosis
living in a low-endemic country do not develop
active disease during a 2 year follow-up; a
Norwegian prospective multicenter study. BMC
Infect Dis 14: 667.
Schön, T., Juréen, P., Chryssanthou, E., Giske, C.G.,
Kahlmeter, G., Hoffner, S., Ängeby, K. 2013.
Rifampicin-resistant and rifabutin-susceptible
Mycobacterium tuberculosis strains: a
breakpoint artefact?. J Antimicrob Chemother
68(9): 2074-7.
Seddon, J.A., Hesseling, A.C., Godfrey-Faussett,
P., Fielding, K., Schaaf, H.S. 2013. Risk factors
for infection and disease in child contacts
of multidrug-resistant tuberculosis: a crosssectional
study. BMC Infect Dis 13:392.
Semunigus, T., Tessema, B., Eshetie, S., Moges, F.
2016. Smear positive pulmonary tuberculosis
and associated factors among homeless
individuals in Dessie and Debre Birhan
towns, Northeast Ethiopia. Ann Clin Microbiol
Antimicrob 15(1): 50.
Tattevin, P., Revest, M., Dupont, M., Arvieux, C.,
Michelet, C. 2003. A regimen containing
rifabutin for the treatment of tuberculosis in
patients intolerant to rifampin. Clin Infect
Dis 36(1): 127-8.
Tessema, B., Muche, A., Bekele, A., Reissig, D.,
Emmrich, F., Sack, U. 2009. Treatment outcome
of tuberculosis patients at Gondar University
Teaching Hospital, Northwest Ethiopia. A five
- year retrospective study. BMC Public Health
9: 371.
Umi Kalthum, M.N., Norfarizal, A., Rona Asnida, N.,
Ayesha, M.Z., Jemaima, C.H. 2012. Bilateral
retinal vasculitis: a presumed case of ocular TB
without inflammation. Med & Health 7(2): 97-
101.
World Health Organization. 2014. Guidance for
national tuberculosis programmes on the
management of tuberculosis in children. 2nd
edition. Geneva: World Health Organization.
